SCHEMBL6323623

SCHEMBL6323623

Cc1ccc(-c2noc(N)c2C(=O)NCCC(c2ccccc2)c2ccccc2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 6/20 0.49
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 2/20 0.44
MTNR1A P48039 1/20 0.42
MTNR1B P49286 1/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGD P15428 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.40
CNR1 P21554 2/20 0.40
CNR2 P34972 2/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA4 P22748 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320941 0.90 EPHX2 (0.47) EPHX2MAPTSMN1; SMN2ALDH1A1MAPK1
SCHEMBL6317382 0.89 CA1 (0.52) EPHX2MAPTSMN1; SMN2ALDH1A1MAPK1
SCHEMBL6324432 0.89 EPHX2 (0.48) EPHX2MAPTSMN1; SMN2ALDH1A1MAPK1
SCHEMBL6316101 0.87 CA1 (0.42) MAPTSMN1; SMN2ALDH1A1NPSR1KDM4E
SCHEMBL6323408 0.85 NPC1 (0.52) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL6324224 0.83 CA1 (0.44) MAPTSMN1; SMN2ALDH1A1MAPK1KDM4E
SCHEMBL6315066 0.83 L3MBTL1 (0.59) MAPTSMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL6317603 0.83 GAA (0.53) MAPTSMN1; SMN2ALDH1A1MAPK1NPSR1
SCHEMBL6324861 0.82 L3MBTL1 (0.55) MAPTSMN1; SMN2ALDH1A1HPGDMEN1
SCHEMBL6315648 0.82 NPSR1 (0.50) EPHX2MAPTSMN1; SMN2ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 EPHX2 4156/4885MAPT 281/4885SMN1; SMN2 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.